Medpace (NASDAQ:MEDP) Price Target Raised to $450.00 at Jefferies Financial Group

Medpace (NASDAQ:MEDP) had its target price boosted by Jefferies Financial Group from $400.00 to $450.00 in a research report report published on Tuesday morning, MarketBeat Ratings reports. Jefferies Financial Group currently has a hold rating on the stock.

A number of other brokerages also recently weighed in on MEDP. UBS Group downgraded shares of Medpace from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Cowen lowered shares of Medpace from a “buy” rating to a “sell” rating in a research report on Wednesday, July 23rd. Robert W. Baird boosted their target price on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research report on Wednesday, July 23rd. Finally, TD Cowen reaffirmed a “sell” rating and issued a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $422.27.

Medpace Stock Down 1.3%

MEDP stock opened at $485.59 on Tuesday. The firm has a market cap of $13.64 billion, a PE ratio of 36.10, a P/E/G ratio of 3.10 and a beta of 1.44. The business has a 50 day moving average of $419.54 and a 200-day moving average of $346.21. Medpace has a 12-month low of $250.05 and a 12-month high of $501.30.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period last year, the company posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, research analysts expect that Medpace will post 12.29 earnings per share for the current year.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares of the company’s stock, valued at approximately $4,654,350. This trade represents a 22.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the transaction, the vice president owned 57,500 shares of the company’s stock, valued at $27,600,000. This represents a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Medpace

A number of large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. raised its stake in shares of Medpace by 55.4% during the 2nd quarter. Osaic Holdings Inc. now owns 6,334 shares of the company’s stock valued at $1,988,000 after purchasing an additional 2,258 shares during the period. Centaurus Financial Inc. grew its holdings in Medpace by 14.7% during the 2nd quarter. Centaurus Financial Inc. now owns 1,852 shares of the company’s stock valued at $581,000 after buying an additional 237 shares in the last quarter. Orion Porfolio Solutions LLC grew its holdings in Medpace by 3.2% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 4,717 shares of the company’s stock valued at $1,480,000 after buying an additional 147 shares in the last quarter. Cim Investment Management Inc. increased its position in shares of Medpace by 100.7% during the second quarter. Cim Investment Management Inc. now owns 2,202 shares of the company’s stock valued at $712,000 after buying an additional 1,105 shares during the period. Finally, Cim LLC increased its position in shares of Medpace by 5.9% during the second quarter. Cim LLC now owns 4,265 shares of the company’s stock valued at $1,339,000 after buying an additional 237 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.